Vascular endothelial growth factor and heparin in a biological glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition

D. A. Weatherford, J. E. Sackman, T. T. Reddick, Michael Freeman, Scott Stevens, Mitchell Goldman

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background. Incomplete luminal endothelialization may contribute to small diameter vascular graft failure. Vascular endothelial growth factor (VEGF) can be used to stimulate endothelialization without provoking smooth muscle cell (SMC) proliferation. Heparin and VEGF in a fibrin glue (FG) were investigated for their ability to promote selective human aortic endothelial cell (HAEC) proliferation and human aortic smooth muscle cell (HASMC) inhibition. Methods. HAECs and HASMCs were seeded on FG containing VEGF (2.5, 10, 30, 100 ng/ml) or VEGF and heparin (5, 50, 500 units/ml). Proliferation assays were performed with tritiated thymidine on days 1 and 3. Results were analyzed by ANOVA, with p ≤ 0.05 significant. Results. HAEC proliferation on FG with 10, 30, and 100 ng/ml VEGF was significantly greater than FG alone at days 1 and 3. The addition of 50 units/ml heparin to VEGF significantly increased HAEC proliferation to greater than FG with VEGF alone at day 1. Human aortic SMC proliferation was not stimulated by the addition of VEGF. The addition of 5, 50, and 500 units/ml heparin significantly inhibited HASMC proliferation regardless of VEGF concentration. Discussion. VEGF at 10 ng/ml combined with heparin at 50 units/ml exhibited maximal stimulation of HAECs with inhibition of HASMCs. VEGF and heparin in a biologic glue may improve patency by selectively promoting HAEC proliferation without HASMC growth on synthetic vascular bypass grafts.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
JournalSurgery
Volume120
Issue number2
DOIs
StatePublished - Jan 1 1996

Fingerprint

Adhesives
Vascular Endothelial Growth Factor A
Smooth Muscle Myocytes
Heparin
Endothelial Cells
Cell Proliferation
Fibrin Tissue Adhesive
Blood Vessels
Transplants
Thymidine
Analysis of Variance

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Vascular endothelial growth factor and heparin in a biological glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition. / Weatherford, D. A.; Sackman, J. E.; Reddick, T. T.; Freeman, Michael; Stevens, Scott; Goldman, Mitchell.

In: Surgery, Vol. 120, No. 2, 01.01.1996, p. 433-439.

Research output: Contribution to journalArticle

@article{60c6903956544bba876137da16bc9f28,
title = "Vascular endothelial growth factor and heparin in a biological glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition",
abstract = "Background. Incomplete luminal endothelialization may contribute to small diameter vascular graft failure. Vascular endothelial growth factor (VEGF) can be used to stimulate endothelialization without provoking smooth muscle cell (SMC) proliferation. Heparin and VEGF in a fibrin glue (FG) were investigated for their ability to promote selective human aortic endothelial cell (HAEC) proliferation and human aortic smooth muscle cell (HASMC) inhibition. Methods. HAECs and HASMCs were seeded on FG containing VEGF (2.5, 10, 30, 100 ng/ml) or VEGF and heparin (5, 50, 500 units/ml). Proliferation assays were performed with tritiated thymidine on days 1 and 3. Results were analyzed by ANOVA, with p ≤ 0.05 significant. Results. HAEC proliferation on FG with 10, 30, and 100 ng/ml VEGF was significantly greater than FG alone at days 1 and 3. The addition of 50 units/ml heparin to VEGF significantly increased HAEC proliferation to greater than FG with VEGF alone at day 1. Human aortic SMC proliferation was not stimulated by the addition of VEGF. The addition of 5, 50, and 500 units/ml heparin significantly inhibited HASMC proliferation regardless of VEGF concentration. Discussion. VEGF at 10 ng/ml combined with heparin at 50 units/ml exhibited maximal stimulation of HAECs with inhibition of HASMCs. VEGF and heparin in a biologic glue may improve patency by selectively promoting HAEC proliferation without HASMC growth on synthetic vascular bypass grafts.",
author = "Weatherford, {D. A.} and Sackman, {J. E.} and Reddick, {T. T.} and Michael Freeman and Scott Stevens and Mitchell Goldman",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0039-6060(96)80320-5",
language = "English (US)",
volume = "120",
pages = "433--439",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Vascular endothelial growth factor and heparin in a biological glue promotes human aortic endothelial cell proliferation with aortic smooth muscle cell inhibition

AU - Weatherford, D. A.

AU - Sackman, J. E.

AU - Reddick, T. T.

AU - Freeman, Michael

AU - Stevens, Scott

AU - Goldman, Mitchell

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Background. Incomplete luminal endothelialization may contribute to small diameter vascular graft failure. Vascular endothelial growth factor (VEGF) can be used to stimulate endothelialization without provoking smooth muscle cell (SMC) proliferation. Heparin and VEGF in a fibrin glue (FG) were investigated for their ability to promote selective human aortic endothelial cell (HAEC) proliferation and human aortic smooth muscle cell (HASMC) inhibition. Methods. HAECs and HASMCs were seeded on FG containing VEGF (2.5, 10, 30, 100 ng/ml) or VEGF and heparin (5, 50, 500 units/ml). Proliferation assays were performed with tritiated thymidine on days 1 and 3. Results were analyzed by ANOVA, with p ≤ 0.05 significant. Results. HAEC proliferation on FG with 10, 30, and 100 ng/ml VEGF was significantly greater than FG alone at days 1 and 3. The addition of 50 units/ml heparin to VEGF significantly increased HAEC proliferation to greater than FG with VEGF alone at day 1. Human aortic SMC proliferation was not stimulated by the addition of VEGF. The addition of 5, 50, and 500 units/ml heparin significantly inhibited HASMC proliferation regardless of VEGF concentration. Discussion. VEGF at 10 ng/ml combined with heparin at 50 units/ml exhibited maximal stimulation of HAECs with inhibition of HASMCs. VEGF and heparin in a biologic glue may improve patency by selectively promoting HAEC proliferation without HASMC growth on synthetic vascular bypass grafts.

AB - Background. Incomplete luminal endothelialization may contribute to small diameter vascular graft failure. Vascular endothelial growth factor (VEGF) can be used to stimulate endothelialization without provoking smooth muscle cell (SMC) proliferation. Heparin and VEGF in a fibrin glue (FG) were investigated for their ability to promote selective human aortic endothelial cell (HAEC) proliferation and human aortic smooth muscle cell (HASMC) inhibition. Methods. HAECs and HASMCs were seeded on FG containing VEGF (2.5, 10, 30, 100 ng/ml) or VEGF and heparin (5, 50, 500 units/ml). Proliferation assays were performed with tritiated thymidine on days 1 and 3. Results were analyzed by ANOVA, with p ≤ 0.05 significant. Results. HAEC proliferation on FG with 10, 30, and 100 ng/ml VEGF was significantly greater than FG alone at days 1 and 3. The addition of 50 units/ml heparin to VEGF significantly increased HAEC proliferation to greater than FG with VEGF alone at day 1. Human aortic SMC proliferation was not stimulated by the addition of VEGF. The addition of 5, 50, and 500 units/ml heparin significantly inhibited HASMC proliferation regardless of VEGF concentration. Discussion. VEGF at 10 ng/ml combined with heparin at 50 units/ml exhibited maximal stimulation of HAECs with inhibition of HASMCs. VEGF and heparin in a biologic glue may improve patency by selectively promoting HAEC proliferation without HASMC growth on synthetic vascular bypass grafts.

UR - http://www.scopus.com/inward/record.url?scp=0029839593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029839593&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(96)80320-5

DO - 10.1016/S0039-6060(96)80320-5

M3 - Article

VL - 120

SP - 433

EP - 439

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -